Unique ID issued by UMIN | UMIN000041465 |
---|---|
Receipt number | R000047337 |
Scientific Title | Measurement of glycemic index (GI) of low GI foods |
Date of disclosure of the study information | 2020/08/19 |
Last modified on | 2021/02/18 09:04:12 |
Measurement of glycemic index (GI) of low GI foods
Measurement of glycemic index (GI) of low GI foods
Measurement of glycemic index (GI) of low GI foods
Measurement of glycemic index (GI) of low GI foods
Japan |
Nothing (Healthy subjects)
Not applicable | Adult |
Others
NO
Measurement of glycemic index (GI) of three kind of low GI foods
Bio-availability
Glycemic index (GI)
120 min after consumption
Incremental blood glucose area under the curve
120 min after consumption
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
3
Prevention
Food |
50g OGTT, 120 min after consumption - wash out period (more than 1 day), 3 times - food-1, 120 min after consumption - wash out period (more than 1 day) - food-2, 120 min after consumption- wash out period (more than 1 day) - food-3, 120 min after consumption
50g OGTT, 120 min after consumption - wash out period (more than 1 day), 3 times - food-2, 120 min after consumption - wash out period (more than 1 day) - food-3, 120 min after consumption- wash out period (more than 1 day) - food-1, 120 min after consumption
50g OGTT, 120 min after consumption - wash out period (more than 1 day), 3 times - food-3, 120 min after consumption - wash out period (more than 1 day) - food-1, 120 min after consumption- wash out period (more than 1 day) - food-2, 120 min after consumption
20 | years-old | <= |
65 | years-old | >= |
Male and Female
(1)Males and females aged 20 to 65 years old.
(2) Subjects whose blood glucose level is under 126 mg/dL.
(3) Subjects who show understanding of the study procedures and agreement with participating the study by written informed consent prior to the study.
(1) Subjects who have under treatment or a history of serious disease(e.g., diabetes, liver disease, kidney disease, or heart disease)
(2)Subjects who suspected chronic or acute infectious disease.
(3)Females who are pregnant or lactating, and females who could become pregnant or lactating during test period.
(4) Subjects whose blood glucose level is under 70 mg/dL.
30
1st name | Naotaka |
Middle name | |
Last name | Kida |
TableMark Company Limited
Research & Development Dept.
144-0042
5-14,Haneda Asahicho Ota-ku, Tokyo 144-0042, JAPAN
03-5705-7562
naotaka.kida@tablemark.co.jp
1st name | Mizuki |
Middle name | |
Last name | Hiranuma |
TableMark Company Limited
Research & Development Dept.
144-0042
5-14,Haneda Asahicho Ota-ku, Tokyo 144-0042, JAPAN
03-5705-7562
mizuki.hiranuma@tablemark.co.jp
TableMark Company Limited
TableMark Company Limited
Self funding
TableMark Company Limited
5-14,Haneda Asahicho Ota-ku, Tokyo 144-0042, JAPAN
03-5705-7562
mizuki.hiranuma@tablemark.co.jp
NO
2020 | Year | 08 | Month | 19 | Day |
Unpublished
Completed
2020 | Year | 08 | Month | 17 | Day |
2020 | Year | 08 | Month | 18 | Day |
2020 | Year | 08 | Month | 24 | Day |
2020 | Year | 09 | Month | 30 | Day |
2020 | Year | 08 | Month | 19 | Day |
2021 | Year | 02 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047337